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The aim of this study was to determine the expression rate of P-glyco-
protein (Pgp), a multidrug resistance marker and the p53 tumour-suppressor protein 
in canine mammary tumours. A total of 30 tumours were examined in parallel to 
patient history. The tumours were allotted to four groups: tubulopapillar carcino-
mas, complex carcinomas, benign tumours, and other malignant tumours. A mono-
clonal mouse antibody (C494) was used for the immunohistochemical evaluation 
of Pgp and a polyclonal rabbit antibody for p53. We found that the intact ductal 
epithelium and connective tissue showed pronounced Pgp expression. The most 
intensive staining was detected in tubulopapillar carcinomas for both Pgp and 
p53. The expression rate of Pgp and p53 differed significantly between tubulo-
papillar carcinoma and complex carcinoma, and between tubulopapillar carci-
noma and benign mammary tumour, respectively. The expressions of Pgp and p53 
highly correlated statistically; therefore, both can determine malignancy in a simi-
lar manner. In the case of tubulopapillar carcinomas, more relapsed tumours oc-
curred than in relation to complex carcinomas and other malignant tumours. Pgp 
expression rate was proportional to the probability of the tumour becoming re-
cidivant postoperatively, as well. These results suggest that routine evaluation of 
Pgp expression in canine mammary tumours may be prognostically helpful. 
Key words: Canine, mammary tumours, multidrug resistance (MDR), P-
glycoprotein (Pgp), p53, immunohistochemistry, therapy resistance, prognostic 
factors 
Mammary neoplasm is one of the most common tumour types in female 
dogs, representing fifty percent of their neoplastic diseases. The most important 
features of primary tumours are recent rapid growth, size, clinical evidence of 
invasiveness (fixation to skin or fascia), ulceration, and clinical evidence of in-
flammatory carcinoma. 
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Carcinomas frequently metastasise to the inguinal lymph nodes, may enter 
the pudendal lymph vessels and spread to the internal iliac lymph nodes. In the 
case of mammary carcinomas the histological subtype has been shown to influ-
ence the survival. Anaplastic carcinoma is characterised by shorter postoperative 
survival (median survival: 2.5 months) than adenocarcinoma (21 months), solid 
carcinoma (16 months), and other types of tumours (24 months). The prognosis 
of mammary sarcomas is very poor; the median survival time of these patients is 
usually 9–12 months. 
The most common sites of distant metastasis are the lungs, the sublumbar, 
sternal and prescapular lymph nodes, the liver and, rarely, bone (Sorenmo et al., 
2013). 
Accurate, precise staging is important before treatment is initiated. The T 
(tumour), N (lymph node) and M (metastasis) staging system should be used for 
dogs with non-inflammatory epithelial tumours and not sarcomas. The most im-
portant requirements of staging are to evaluate the primary tumour and the re-
gional lymph nodes, and to attempt to identify any distant metastatic sites, in-
cluding distant lymph nodes and the lungs (Sorenmo et al., 2013). The magnetic 
resonance imaging (MRI) technique is available for use in the routine examina-
tion of canine mammary glands and staging; the MRI findings are in close corre-
lation with the histological result (Garamvölgyi et al., 2006). 
Histological classification is very important for the exact prognosis. Apart 
from the routine haematoxylin and eosin staining, it is very important to identify 
the histogenetic origin and the immunophenotype of tumour cells (Sorenmo et 
al., 2013). 
Canine mammary tumours may be characterised by histological classification 
as malignant or benign tumours. The malignant tumours include non-infiltrating 
(in situ) carcinoma, complex carcinoma, simple carcinoma (tubulopapillary car-
cinoma, solid carcinoma, and anaplastic carcinoma), special types of carcinomas 
(spindle cell carcinoma, squamous cell carcinoma, mucinous carcinoma, and 
lipid-rich carcinoma), sarcoma, fibrosarcoma, and osteosarcoma, other sarcomas 
such as carcinosarcoma, carcinoma or sarcoma in benign tumour (Goldschmidt et 
al., 2011). 
In the group of benign tumours, adenoma (simple adenoma, complex ade-
noma, basaloid adenoma), fibroadenoma (low-cellularity fibroadenoma, high-
cellularity fibroadenoma), benign mixed tumour, and duct papilloma are known 
(Hellmén, 1996). 
The proliferation capacity of neoplastic cells is one of the most important 
characteristics of tumours. This determines the degree of malignancy, i.e. the 
grade. The grade represents important prognostic information, because the be-
haviour of mammary tumours has been shown to be predicted by the grade. For 
grading, the degree of differentiation, the mitotic index, the degree of cellular or 
nuclear polymorphism and the size and number of nucleoli are needed. Some of 
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these may be observed by routine histological examination. Other specific tests 
are the examination of the Ki-67 growth factor (Kiupel et al., 1998) and the sil-
ver staining of nucleolar organiser regions (AgNORs) (Juntes et al., 1995; 
Destexhe et al., 1995; Crocker et al., 1998). There are some other tests as well: 
malignant tumours have low progesterone expression (Thuróczy et al., 2007), 
and the evaluation of microvessel density by claudin-5 immunohistochemistry 
may give useful additional information on the angiogenic potential of mammary 
cancers in dogs (Jakab et al., 2008). 
Apart from the detection of prognostic markers, the ability of the mam-
mary tumour to develop therapy resistance is equally relevant. Lately, multidrug 
resistance (MDR) has become one of the most important problems in the man-
agement of oncological patients, because in most of the cases MDR is responsi-
ble for the failure of chemotherapy. One of the most important factors inducing 
MDR is the P-glycoprotein (Pgp), an ATP-dependent efflux-pump protein and its 
classical form is the product of the mdr-1 gene. The role of Pgp in the MDR 
mechanism is that it removes xenobiotics, including chemotherapeutic agents, 
from the cell; therefore, the level of chemotherapeutic agents cannot reach the 
minimal intracellular drug concentration necessary for successful chemotherapy. 
The substrates of Pgp are chemotherapeutic agents such as vincristine, doxorubi-
cin, actinomycin D and mitoxantrone. Approximately 33.3% of mammary ade-
nomas and 63.2% of mammary carcinomas express Pgp (Ginn, 1996). 
In human and also in veterinary oncology, high Pgp expression is proven 
to be a negative prognostic factor in many types of tumours. In human oncology, 
it has been known for a long time that a correlation exists between high Pgp level 
and MDR in the case of mammary neoplasms (Sanfilippo et al., 1991). 
In addition to Pgp, there are other known factors that may also cause MDR, 
e.g. the multidrug resistance associated protein (MRP), the lung resistance associ-
ated protein (LRP), the topoisomerases, and the glutathions (Bergman, 1999). 
The p53 protein is known to be a tumour suppressor. It is an important 
part of the self-regulating system of the cell. It reduces the expression of the pro-
liferating cell nuclear antigen (PCNA) and the MDR genes, and by this mecha-
nism it blocks tumorigenesis caused by neoplastic mutations. In canine mam-
mary tumours, Veldhoen et al. (1999) have found that the ‘germ line’ region of 
the gene encoding the p53 protein suffered a point mutation, and the protein 
translated from the gene became inactive. These defective proteins do not have 
any tumour suppressor effect, but in the cytoplasm or in the nucleus an overex-
pression can be detected by immunohistochemical examinations, because the 
hapten serving as the basis of detection is mutated, and the original proteins bind 
the antibody used in the determination (Lee et al., 2004). The degree of expres-
sion of the mutated p53 shows a correlation with malignancy and shorter survival 
time (Chu et al., 1998). Mutation of p53 was demonstrated in more than 50% of 
human tumours including mammary neoplasms, as well. 
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Materials and methods 
Tissue samples 
Mammary tumours of 30 dogs of different ages and breeds were exam-
ined. The dogs were operated on at the Department and Clinic of Reproduction, 
Faculty of Veterinary Science, Szent István University. Age ranged from 5 to 13 
years in the following distribution: 5 years old (n = 3), 6 years old (n = 4), 8 
years old (n = 5), 9 years old (n = 3), 10 years old (n = 4), 11 years old (n = 3), 
12 years old (n = 6), and 13 years old (n = 2). Routine histological classification 
of the tumours resulted in 9 tubulopapillary carcinomas, 12 complex carcinomas, 
2 complex adenomas, 2 benign mixed tumours, 1 fibroadenoma, 2 carcinosar-
coma, and 1 lipid-rich complex carcinoma. 
The samples were fixed in 4% neutral buffered formalin and embedded in 
paraffin. For the preparation of the sections we used commercial xylanised slides. 
The paraffin slides were incubated at 56 °C for 12 h. Samples were processed up 
to this phase at the Department of Pathology of the Central Veterinary Institute, 
Budapest. 
The detection of Pgp 
The method was based on the study of Ginn (1996) and on the recommen-
dations of the National Institute of Oncology (Budapest). We performed the im-
munohistochemistry in the Laboratory of the Department and Clinic of Internal 
Medicine, Faculty of Veterinary Science, Szent István University, Budapest. 
Formalin-fixed sections were deparaffinised and rehydrated through se-
quential immersions in xylene followed by changes of graded concentrations of 
ethanol. We blocked the activity of the endogenous peroxidase with 3% hydro-
gen peroxide solution. After treatment with appropriate antigen retrieval solution 
(Retrieve All 1 solution, Signet Laboratories, Dedham, USA, 90 °C, diluted 1:3 
with PBS), nonimmune binding of antiserum was blocked by incubating sections 
in PBS supplemented with 4% normal horse serum (1:10 dilution, Vector Labo-
ratories, Burlingame, USA). Each tissue section was incubated for 60 min at 
room temperature with the primary monoclonal antibody against Pgp (C494, 
Signet Laboratories) properly diluted in PBS containing 4% equine serum. Im-
munohistochemical labelling was performed using the streptavidin-peroxidase 
procedure. Antigen-bound primary antibody was detected using standard avidin-
biotin immunoperoxidase complex (Vectastain Elite ABC Kit). The slides were in-
cubated for 45 min with biotinylated horse anti-mouse antibody; the chromogen 
substrate was 3, 3’-diaminobenzidine tetrahydrochloride (DAB, Vector Labora-
tories). Sections were counterstained with haematoxylin and mounted (DPX 
mountant, BDH Laboratory Supplies). 
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The positive control was a formalin-fixed, paraffin-embedded section of 
canine liver and kidney tissue from a healthy dog. The negative control was a 
healthy canine lymph node tissue. 
The detection of p53 
The method used for the immunohistochemical detection of p53 was based 
on the study of Wolf et al. (1997). The staining was performed in the Laboratory 
of the Department and Clinic of Internal Medicine. 
To deparaffinise and rehydrate the samples we used the same method as 
described previously for the detection of Pgp. Tissue sections were then incu-
bated in preheated (90 °C) citrate solution diluted in PBS (1:10) as a means of 
unmasking antigens. Nonimmune binding of antiserum was blocked by incubat-
ing sections in PBS supplemented with 4% normal goat serum (1:10 dilution, 
Vector Laboratories). The sections were incubated overnight at room tempera-
ture with the primary antibody against p53 (1:75 dilution, CM-1, polyclonal rab-
bit anti-human p53 oncoprotein, Signet Laboratories). The next steps of the stain-
ing were the same as those of the Pgp staining, except in this case biotinylated 
goat anti-rabbit antibody was used. Human breast adenocarcinoma served as 
positive control, the negative control was healthy canine lymph node. 
The distribution and intensity of labelling were analysed by light micros-
copy. The percentage of Pgp-positive cells was evaluated semiquantitatively and 
independently by the two authors who were unaware of the origin of samples, by 
counting the number of labelled cells in 10 fields (× 400) or at least 500 cells. 
The expression percentage was determined by dividing the number of labelled 
cells by the total number of counted cells for each specimen. Nuclear and cyto-
plasmic expressions were noted but were not included in the scoring. 
The expression percentage of p53 cells was determined by methods similar 
to those described for Pgp. Nuclear and cytoplasmic expressions were not counted 
separately, because nuclear staining was not seen in 56% of the specimens. The 
method used and the results obtained were similar to those of Lee et al. (2004). 
Statistical procedures 
Based on the results of histological classification, we divided our patients 
into 4 groups: tubulopapillary carcinoma (n = 9), complex carcinoma (n = 12), 
benign tumour (n = 6), other malignant tumour (n = 3). Inter-group comparisons 
were made for the following factors: whether or not the patient had been neu-
tered before the occurrence of mammary tumour; age of the patients at the opera-
tion; primary neoplasm or a relapsed tumour; presence of lymph node metastasis 
or other signs of invasiveness; presence of relapse; occurrence of other types of 
tumour before/after the operation; whether the cause of death was an oncological 
disease or some other condition. 
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Fig. 1. Expression of Pgp and p53 in canine mammary tumours. The neoplastic cells show a moderate to strong intensity of immunoreactivity.  
The expression appeared mainly as cytoplasmic staining, with some cells also showing a perinuclear localisation. A: Expression of p53 in  
tubulopapillary carcinoma. Avidin-biotin-peroxidase complex method, CM-1 polyclonal antibody, Mayer’s haematoxylin counterstain, × 1000.  
B: Expression of Pgp in complex carcinoma. Avidin-biotin-peroxidase complex method, C494 monoclonal antibody, Mayer’s haematoxylin  
counterstain, × 1000. C: Expression of p53 in complex adenoma. Avidin-biotin-peroxidase complex method, CM-1 polyclonal antibody, Mayer’s 
haematoxylin counterstain, × 1000. D: Expression of Pgp in tubulopapillary carcinoma. Avidin-biotin-peroxidase complex method,  
C494 monoclonal antibody, Mayer’s haematoxylin counterstain, × 1000 
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To compare groups, we used Wilcoxon rank-sum test and independent 
two-sample t-test with unequal variance (SAS-STAT software). 
Pearson’s analysis was also performed in order to find correlations among 
variables. 
 
Results 
Pgp expression was pronounced in the intact ductal epithelium and in the 
connective tissue (Fig. 1). The same type of cell occurs in tubulopapillary can-
cers after neoplastic transformation; therefore, this type of tumour cell shows 
similarly high Pgp expression. We used Wilcoxon rank-sum test to compare the 
Pgp and p53 expression rates in the different types of mammary tumours. We 
observed statistically significant differences in the expression rate of Pgp and 
p53 between tubulopapillary carcinoma and complex carcinoma, and between 
tubulopapillary carcinoma and benign mammary tumour (Table 1). 
Table 1 
Comparison of different types of tumours in terms of Pgp and p53 expression rate 
 Pgp (%) p53 (%) 
I. Tubulopapillary carcinoma 66.9 ± 20.1 85.6 ±7.3 
II. Complex carcinoma 35.7 ± 22.5 66.5 ± 18.4 
III. Benign tumour 25.0 ± 29.5 43.3 ± 19.3 
IV. Other malignant tumour 33.3 ± 29.5 30.0 ± 15.0 
P-value: I–II 0.0052 0.0146 
P-value: I–III 0.0002 0.0847 
P-value: I–IV 0.2431 0.1577 
P-value: II–III 0.1683 0.2234 
P-value: II–IV 0.9215 0.2098 
P-value: III–IV 0.7296 0.5665 
P-value: I, II, IV–III 0.001773 0.173513 
 
We observed that in patients with tubulopapillary carcinoma, significantly 
more relapsed tumours occurred later than in patients with any other types of tu-
mours. We found lymph node metastasis associated only with complex carcino-
mas and carcinosarcomas (Table 2). 
The patients’ history data were also compared. The fact that the patient 
had been previously spayed was taken into consideration, because it is well 
known that neutering decreases the probability of development of canine mam-
mary tumours (Schneider et al., 1969). We compared the age at tumour occur-
rence, and in these cases we could not find any significant differences among the 
tumour types. 
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The results indicate that neutering at more than two years of age did not 
affect the occurrence of the tumours significantly. Dogs with tubulopapillary car-
cinoma had been spayed in a higher ratio, but at an older age (3–4 years). In the 
spayed bitches tumours developed by the age of 8–9 years as well; furthermore, 
most of these cases later relapsed. 
The survival time of dogs with tubulopapillary and complex carcinomas 
was significantly shorter than that of dogs with benign tumours. Also, dogs with 
benign tumours had longer survival times than those with other (non-carcinoma) 
types of tumour (Table 3). 
We found that the expressions of Pgp and p53 were correlated. The level 
of Pgp expression correlated also with the probability of tumour recurrence after 
the operation and was inversely related to the survival time. An inverse, but non-
significant, correlation was determined between p53 expression and survival 
time (Table 4). 
Table 4 
Correlation of variables in canine mammary gland tumours 
Parameters compared Correlation coefficient (R)  
Pgp : p53 0.55 P < 0.01 
Pgp : Relapse, later 0.484 P < 0.01 
Pg: Survival time –0.287 P < 0.05 
p53: Survival time –0.122 nonsignificant 
 
As regards p53 expression, no correlation was found either between the 
nuclear and the cytoplasmic expression (r = –0.044) or between the nuclear ex-
pression and the survival time (r: –0.145, P = 0.479). 
 
 
Discussion 
In this study we demonstrated that there are significant differences in the 
expression rate of Pgp between tubulopapillary carcinoma and complex carci-
noma as well as between tubulopapillary carcinoma and benign mammary tu-
mour. Because of these high levels, these tumours may be considered the most 
resistant tumour types. In these tumours, there is a lower chance to perform a 
successful chemotherapy, especially with drugs that are substrates of Pgp 
(doxorubicin, vincristine, cyclophosphamide, mitoxantrone). 
Petterino et al. (2006) had compared the ratio of Pgp-positive cells in tu-
bulopapillar carcinomas (49.75%), complex carcinomas (40.31%), benign tu-
mours (31.36%) and carcinosarcomas (47.28%). In comparison to their results, 
the Pgp positivity data obtained in this study were slightly different: 66.94% in 
tubulopapillar carcinomas, 35.72% in complex carcinomas, 25% in benign tu-
 EXPRESSION OF Pgp AND p53 PROTEINS IN CANINE MAMMARY TUMOURS 203 
Acta Veterinaria Hungarica 62, 2014 
mours, and 33.33% in carcinosarcomas. However, the results obtained by the two 
research groups do not differ significantly. 
In contrast to lymphoma, almost all mammary cancer samples showed a 
certain degree of Pgp expression. Presumably, this phenomenon indicates that if 
a mammary cancer with lower Pgp expression were treated, after the initial tu-
mour regression a therapy-resistant clone would emerge, which after prolifera-
tion would not show regression in response to therapy. 
In the present study, Pgp immunostaining values showed a correlation 
with the survival time regardless of the tumour type. Although the survival time 
was the shortest in tubulopapillary carcinomas, the Pgp values did not differ sig-
nificantly from each other. 
Regarding the expression of p53, it is remarkable that we have found posi-
tive staining in the benign tumours as well, although at a lower rate than in tubu-
lopapillar or complex carcinomas. The positivity for p53 is not surprising in ade-
nomas either (Wolf et al., 1997). In another paper it was reported that most car-
cinomas showed as high as 32% positive staining for p53 (Rodo and Malicka, 
2008). However, in our study a higher expression rate was detected. The source 
of this discrepancy may be the detection method used, because Rodo and Ma-
licka (2008) counted only stained nuclei, while in the present study we counted 
both the nuclear and the cytoplasmic staining. 
In our study, tubulopapillar carcinomas were tumours originating almost 
only from recurrence, which was not unexpected as this type of neoplasm often 
relapses. Concerning age at occurrence, there was no significant difference be-
tween the tumour types. In contrast to data reported in the scientific literature 
(Schneider et al., 1969), neutering of patients at more than two years of age did 
not provide protection against carcinogenesis. The reason for this difference may 
be that the dogs examined in this study were probably spayed at an older age. 
We demonstrated that the expressions of Pgp and p53 were related. This 
implies that both the expression of the protein causing therapy resistance and the 
overexpression of the mutant p53 can help in the detection of malignancy. There-
fore, the detection of Pgp expression may be a valuable prognostic parameter in 
dogs with mammary tumours, even if the animals are not treated with chemo-
therapy but only by surgery. 
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